Michael T. Henry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael T. Henry has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
C. Costello
Department of Medicine and Therapeutics, University College, Dublin, Ireland
1 shared publicationC. M. O'Connor
Department of Medicine and Therapeutics, University College, Dublin, Ireland
1 shared publicationK. McMahon
Department of Medicine and Therapeutics, University College, Dublin, Ireland
1 shared publicationLeslie A. Davidson
1 shared publicationM. X. Fitzgerald
Department of Medicine and Therapeutics, University College, Dublin, Ireland
1 shared publicationNigel J. Cooke
1 shared publication
Latest Publications
- 1 January 2002
- Published by Taylor & Francis in Experimental Lung Research
- Vol. 28 (2) , 85-97
SECRETORY LEUKOCYTE PROTEINASE INHIBITOR AND ELAFIN ARE RESISTANT TO DEGRADATION BY MMP-8
The naturally occurring neutrophil elastase inhibitors, alpha1-proteinase inhibitor (alpha1PI), secretory leukocyte proteinase inhibitor (SLPI), and elafin, are potential therapeutic agents in the treatment of neutrophil-mediated lung disease. However alpha1PI has been shown to be susceptible to inactivation by matrix metalloproteinases (MMPs) released by neutrophils, particularly neutrophil collagenase (MMP-8). The aim of this study was to determine if SLPI and elafin are similarly susceptible to degradation by this neutrophil-specific MMP. The effect of MMP-8 on SLPI and elafin was assessed by determining the neutrophil elastase inhibitory capacity (NEIC) and electrophoretic protein profile of both inhibitors following exposure to purified MMP-8. As a positive control, the effect of MMP-8 alpha1PI was assessed in parallel. Although treatment of alpha1PI with MMP-8 resulted in a significant decrease in its NEIC (P = .025), no similar decrease was observed with SLPI or elatin. Electrophoretic analysis confirmed digestion of alpha1PI by MMP-8 but no digestion of either SLPI or elafin was observed. These results demonstrate that SLPI and elafin are resistant to proteolytic inactivation by MMP-8, a property that may enhance their therapeutic application in neutrophil-mediated inflammatory lung disease.
- 1 January 2002
- Published by Taylor & Francis in Experimental Lung Research
- Vol. 28 (2) , 85-97
SECRETORY LEUKOCYTE PROTEINASE INHIBITOR AND ELAFIN ARE RESISTANT TO DEGRADATION BY MMP-8
The naturally occurring neutrophil elastase inhibitors, alpha1-proteinase inhibitor (alpha1PI), secretory leukocyte proteinase inhibitor (SLPI), and elafin, are potential therapeutic agents in the treatment of neutrophil-mediated lung disease. However alpha1PI has been shown to be susceptible to inactivation by matrix metalloproteinases (MMPs) released by neutrophils, particularly neutrophil collagenase (MMP-8). The aim of this study was to determine if SLPI and elafin are similarly susceptible to degradation by this neutrophil-specific MMP. The effect of MMP-8 on SLPI and elafin was assessed by determining the neutrophil elastase inhibitory capacity (NEIC) and electrophoretic protein profile of both inhibitors following exposure to purified MMP-8. As a positive control, the effect of MMP-8 alpha1PI was assessed in parallel. Although treatment of alpha1PI with MMP-8 resulted in a significant decrease in its NEIC (P = .025), no similar decrease was observed with SLPI or elatin. Electrophoretic analysis confirmed digestion of alpha1PI by MMP-8 but no digestion of either SLPI or elafin was observed. These results demonstrate that SLPI and elafin are resistant to proteolytic inactivation by MMP-8, a property that may enhance their therapeutic application in neutrophil-mediated inflammatory lung disease.
- 1 December 2001
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 13 (12) , 1495-1497
Tracheobronchial involvement with Crohn's disease
We report the case of a young woman with Crohn's disease of the bowel who presented with a purulent tracheobronchitis and life-threatening upper airway obstruction. Fibreoptic bronchoscopy demonstrated severe tracheal and upper bronchial pseudotumours and stenosis. The role of recent discontinuation of corticosteroids, for quiescent inflammatory bowel disease, in the development of endobronchial disease and the dramatic response in airway patency after reintroduction of prednisolone in this rare complication of Crohn's disease are discussed.
- 1 December 2001
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 13 (12) , 1495-1497
Tracheobronchial involvement with Crohn's disease
We report the case of a young woman with Crohn's disease of the bowel who presented with a purulent tracheobronchitis and life-threatening upper airway obstruction. Fibreoptic bronchoscopy demonstrated severe tracheal and upper bronchial pseudotumours and stenosis. The role of recent discontinuation of corticosteroids, for quiescent inflammatory bowel disease, in the development of endobronchial disease and the dramatic response in airway patency after reintroduction of prednisolone in this rare complication of Crohn's disease are discussed.